Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASKA Pharmaceutical Holdings Co has a current ratio of 2.76. It generally indicates good short-term financial strength.
The historical rank and industry rank for ASKA Pharmaceutical Holdings Co's Current Ratio or its related term are showing as below:
TSE:4886'
s Current Ratio Range Over the Past 10 Years
Min: 2.34 Med: 2.76 Max: 3.1
Current: 2.76
During the past 5 years, ASKA Pharmaceutical Holdings Co's highest Current Ratio was 3.10. The lowest was 2.34. And the median was 2.76.
TSE:4886's Current Ratio is ranked better than 63.93% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs TSE:4886: 2.76
ASKA Pharmaceutical Holdings Co (TSE:4886) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
ASKA Pharmaceutical Holdings Co Current Ratio Related Terms
ASKA Pharmaceutical Holdings Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASKA Pharmaceutical Holdings Co Current Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ASKA Pharmaceutical Holdings Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where ASKA Pharmaceutical Holdings Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASKA Pharmaceutical Holdings Co (TSE:4886) has a Current Ratio of 2.76 as of Mar. 2026. This is near median its historical median of 2.76. Over the past decade, ASKA Pharmaceutical Holdings Co's Current Ratio has ranged from 2.34 to 3.10. According to the industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #360 out of 998 companies in the Drug Manufacturers industry, placing it in the top 36.1%.
Is ASKA Pharmaceutical Holdings Co's Current Ratio too high?
ASKA Pharmaceutical Holdings Co's current Current Ratio of 2.76 is near median its 10-year median of 2.76. Over the past 10 years, this metric has ranged from a low of 2.34 to a high of 3.10. The Drug Manufacturers industry median Current Ratio is 2.00. ASKA Pharmaceutical Holdings Co's value of 2.76 is 38% above this industry median. Based on the distribution chart, ASKA Pharmaceutical Holdings Co ranks #360 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ASKA Pharmaceutical Holdings Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ASKA Pharmaceutical Holdings Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ASKA Pharmaceutical Holdings Co ranks #360 out of 998 companies for Current Ratio. This puts ASKA Pharmaceutical Holdings Co in the upper half of its industry. The industry median Current Ratio is 2.00. ASKA Pharmaceutical Holdings Co's value of 2.76 is 38% above this benchmark. Historically, ASKA Pharmaceutical Holdings Co's own Current Ratio has ranged from 2.34 to 3.10 over the past decade. While the company's 10-year median is 2.76 vs. the industry median of 2.00, ASKA Pharmaceutical Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ASKA Pharmaceutical Holdings Co's current Current Ratio of 2.76 is 38% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ASKA Pharmaceutical Holdings Co's current Current Ratio is 2.76, which is near median its own 10-year median of 2.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASKA Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co (TSE:4886) is currently considered Fairly Valued. The stock's GF Value™ is 円2,402.70, compared to a current price of 円2,244.00 — trading 6.6% below its estimated fair value. The current Current Ratio is 2.76, which is near median its 10-year median of 2.76 and 38% above the Drug Manufacturers industry median of 2.00. ASKA Pharmaceutical Holdings Co's overall GF Score™ is 61/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For ASKA Pharmaceutical Holdings Co (TSE:4886), the current Current Ratio is 2.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ASKA Pharmaceutical Holdings Co (TSE:4886) Overvalued in 2026?
Based on GuruFocus' analysis, ASKA Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of 円2,244.00 is trading 6.6% below its estimated GF Value™ of 円2,402.70.
GuruFocus considers ASKA Pharmaceutical Holdings Co to be Fairly Valued.
Key valuation signals for TSE:4886:
Current Ratio: 2.76 (near median its 10-year median of 2.76)
GF Value™: 円2,402.70 vs. price of 円2,244.00 (6.6% below fair value)
Industry Position: 38% above the Drug Manufacturers median (#360 of 998)
No single metric tells the full story. See the TSE:4886 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ASKA Pharmaceutical Holdings Co Business Description
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and other related operations.
61GF Score
Get the complete analysis for TSE:4886
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4886 has been successfully added to your 
